Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DENTSPLY SIRONA Inc. (Nasdaq: XRAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, strategic reviews and key governance decisions.
In its Form 8-K filings, Dentsply Sirona reports results of operations and financial condition for recent quarters, including segment and geographic performance, non-GAAP metrics and information about goodwill and intangible asset impairments. The company also files 8-Ks to disclose changes in executive officers, retention equity incentive awards, formation of board-level committees and updates on matters such as the conclusion of an SEC Division of Enforcement investigation without enforcement action.
Other filings referenced by the company, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, contain detailed risk factors, financial statements and management discussion that are incorporated by reference in forward-looking statements. These documents provide context on how Dentsply Sirona views risks related to its dental products, technologies, segments and global operations.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the significance of each document in straightforward language. Real-time updates from EDGAR help users follow new 8-Ks reporting quarterly earnings, leadership transitions or strategic portfolio decisions, as well as periodic reports like 10-K and 10-Q when available. For those monitoring governance and incentives, filings also describe compensation arrangements, retention grants and board committee structures. This page is a focused resource for understanding how Dentsply Sirona communicates material information, manages regulatory obligations and frames risks and opportunities in its official SEC documents.
DENTSPLY SIRONA Inc. executive Kevin Czerney, the Vice President and Chief Accounting Officer, reported acquiring 1,478 shares of common stock as a grant or award at a price of $0.00 per share. After this award, his directly owned holdings increased to 29,630.908 shares of the company’s common stock.
The award relates to performance-based restricted stock units granted on March 3, 2023, which were certified as attained on March 2, 2026 after the company met specified performance criteria. According to the award terms, these PRSUs vest and convert into shares of common stock on March 3, 2026.
DENTSPLY SIRONA Inc. director James D. Forbes bought 5,000 shares of common stock in an open-market purchase. The shares were acquired at a price of $13.469 per share on 2026-03-03, giving him direct ownership of 5,000 shares following the transaction.
DENTSPLY SIRONA Inc. director Brian P. McKeon filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing establishes his reporting status as a director of the company but does not report any specific buy or sell transactions.
DENTSPLY SIRONA Inc. director James D. Forbes filed an initial ownership report on Form 3. This filing establishes his status as an insider, including his role as a director of the company. The Form 3 does not report any share purchases or sales, and serves as a baseline disclosure of his insider position.
Dentsply Sirona Inc. filed its annual report describing a large global business focused on professional dental products, digital equipment, clear aligners, implants and continence care, selling into about 140 countries through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.
The company highlights long-term industry tailwinds such as aging populations, aesthetic dentistry, digital workflows and emerging-market demand, and notes that roughly two-thirds of dental products are sold through distributors, with Henry Schein and Patterson each representing around or above 10% of sales or receivables in some years.
Management plans to increase research and development to about 5% of net sales beginning in 2026, emphasizing cloud-based DS Core, CAD/CAM systems and AI-powered tools. The report describes significant cybersecurity, data-privacy and AI-related risks, as well as extensive global regulatory requirements for medical devices, anti-bribery, and data protection.
Dentsply Sirona outlines recent and ongoing restructuring programs, including a 2026 plan expected to generate about $120 million in annualized cost savings after non-recurring charges of approximately $55–$65 million, and discusses risks from ERP implementation, tariffs, geopolitical tensions, and a German tax investigation tied to past intercompany loans.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported a small share disposition tied to equity compensation. On the transaction date, 1,194.48 shares of common stock were withheld at a price of $13.14 per share to cover taxes on vested restricted stock units and related dividend equivalent units. After this tax-withholding disposition, Scavilla directly owned 16,750.066 shares of DENTSPLY SIRONA common stock.
Dentsply Sirona reported Q4 2025 net sales of $961 million, up 6.2%, but a net loss of $146 million or ($0.74) per share, mainly from $144 million of goodwill and intangible impairments. Full-year 2025 net sales were $3.68 billion, down 3.0%, with a net loss of $598 million or ($3.00) per share.
On a non-GAAP basis, Q4 adjusted EPS was $0.27 and full-year adjusted EPS was $1.60. The company generated Q4 free cash flow of $60 million and full-year free cash flow of $104 million, ending 2025 with $326 million in cash and cash equivalents.
The Board approved a restructuring plan expected to create about $120 million in annualized cost savings, with $55–$65 million in non-recurring charges largely in 2026–2027. Dentsply Sirona also eliminated its quarterly dividend to redirect capital toward debt reduction and share repurchases. For 2026, it targets net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
DENTSPLY SIRONA Inc. increased the size of its Board of Directors from 11 to 13 members and appointed James D. Forbes and Brian P. McKeon as new directors, effective February 27, 2026. They will serve until the director elections at the 2026 annual meeting of stockholders.
Forbes, a veteran healthcare investment banker with experience advising on more than $200 billion in financings and over $100 billion in M&A, will join the Compensation & Human Capital Committee. McKeon, a long-tenured public company CFO and director, will join the Audit and Finance Committee and the Science and Technology Committee.
The company highlights that their strategic and financial expertise is intended to support execution of its Return-to-Growth action plan and long-term value creation efforts. Long-serving director Willie A. Deese plans to retire from the Board and will not stand for re-election, and his decision is stated not to result from any disagreement with the company.
Lazard Asset Management LLC reported beneficial ownership of 8,733,942 shares of DENTSPLY SIRONA Inc, representing 4.4% of the equity class as of 12/31/2025. Lazard has sole power to vote and dispose of all these shares.
The firm states the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of DENTSPLY SIRONA, nor in connection with any control-related transaction.
AQR Capital Management Holdings, LLC and its wholly owned subsidiary AQR Capital Management, LLC report beneficial ownership of DENTSPLY SIRONA Inc. common stock. They disclose beneficially owning 4,898,136 shares, representing 2.45% of the outstanding common stock.
The firms report shared voting and dispositive power over all of these shares and no sole voting or dispositive power. They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of DENTSPLY SIRONA.